StonvexLoading…
StonvexStonvexStonvexCore line items from INMD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $370.50M | $394.82M | $492.05M | $454.27M |
Operating Income | $85.39M | $112.53M | $195.66M | $197.85M |
Net Income | $93.83M | $181.28M | $197.92M | $161.52M |
EPS (Diluted) | $1.43 | $2.25 | $2.30 | $1.89 |
Total Assets | $766.43M | $785.67M | $863.29M | $644.41M |
Total Liabilities | $83.23M | $81.85M | $75.91M | $89.79M |
Cash & Equivalents | $302.54M | $155.33M | $144.41M | $97.54M |
Free Cash Flow OCF − CapEx | $84.28M | $132.00M | $176.12M | $180.00M |
Shares Outstanding | 63.36M | 69.56M | 83.98M | 82.54M |